Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.

Abstract: An antigen and antibodies prepared based on peptidylarginine deiminase (PADI4) serving as a tumor marker, and application thereof are disclosed. The antigen has an amino acid sequence shown as SEQ ID NO. 1. Specific antibodies prepared by using the antigen are also disclosed. The protein PADI4 monoclonal antibodies include a protein PADI4 monoclonal antibody coated onto an ELISA plate and a biotin-labeled protein PADI4 monoclonal antibody. A kit prepared by using the antibodies of the present disclosure can effectively and stably determine a protein PADI4 level of a human serum, and has a broad spectrum, detectability, and high test repeatability.